MET and acute myeloid leukemia: Based on this background and in vitro studies that suggested efficacy from targeting both the MET and FGF receptor pathways simultaneously in AML, a phase 1 clinical trial using the rational combination of the MET inhibitor merestinib and the FGFR inhibitor LY2874455 was conducted in patients with relapsed or refractory acute myeloid leukemia [200].